regardless of encouraging clinical evidence, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering considerable difficulty from PBMs. Such insurers are often building barriers to reimbursement, such as high cost restrictions and prior authorization that hinder consumer availability. Market indi